Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived⦠read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
$1.53
Price-4.69%
-$0.07
$20.220m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$10.190m
-
1y CAGR-
3y CAGR-
5y CAGR-$28.12
-
1y CAGR-
3y CAGR-
5y CAGR$9.743m
$10.108m
Assets$364.630k
Liabilities$21.330k
Debt0.2%
-
Debt to EBITDA-$8.823m
-
1y CAGR-
3y CAGR-
5y CAGR